U.S. markets closed

Urovant Sciences Ltd. (UROV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.160.00 (0.00%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close16.16
Open16.17
Bid16.05 x 800
Ask16.25 x 800
Day's Range16.15 - 16.19
52 Week Range6.55 - 16.25
Volume44,330
Avg. Volume339,919
Market Cap512.611M
Beta (5Y Monthly)2.35
PE Ratio (TTM)N/A
EPS (TTM)-5.15
Earnings DateNov 02, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • ACCESSWIRE

    Lifshitz Law Firm, P.C. Announces Investigation of CBMG, HMSY, UROV, and WDR

    NEW YORK, NY / ACCESSWIRE / January 18, 2021 / Lifshitz Law Firm, P.:Cellular Biomedicine Group, Inc.

  • GlobeNewswire

    ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROV

    NEW YORK, Jan. 16, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click here to learn more about your rights and options. Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX in exchange for a number of shares of its common stock, with current equity holders of Cancer Genetics expected to own 22% of the common stock of the combined company. If you are a Cancer Genetics shareholder, click here to learn more about your rights and options. Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sumitovant Biopharma Ltd. for $16.25 per share. If you are an Urovant shareholder, click here to learn more about your rights and options. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information:Halper Sadeh LLPDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.com

  • SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger
    PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following Merger

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: